Bivalent booster failure, low & failed vaccine effectiveness, viral immune escape, original antigenic sin & immune imprinting/fixation & antibody-dependent enhancement of infection (ADEI); 3 studies

by Paul Alexander

I remind you of these three (3) recent studies that show the failure of the bivalent booster (comprised of the initial legacy Wuhan strain & BA.5 spike)

Make no mistake, this is original antigenic sin (OAS) (I call it mortal antigenic sin due to immune priming or fixation or prejudicing to wards the initial prime or exposure).

We are seeing in the body of research that risk of COVID infection escalates based on the number of shots you receive.

Once again as a reminder, a mass vaccination roll-out into a pandemic (in the midst of an ongoing pandemic) across all age groups and with ‘rapid’ mass vaccination at that, while there is massive infectious pressure (circulating virus trying to infect the population) and using a non-neutralizing vaccine whereby the virus has become largely resistant to the vaccine induced antibodies (now antibodies are non-sterilizing, non-neutralizing so does not stop infection, replication, or transmission), then selection pressure (natural selection) will select for the most ‘fittest’ infectious variants that would become enriched in the environment and now become the new dominant variants e.g. BQ.1.1 now replaces BA.5. There is original antigenic sin (OAS and I call it ‘mortal’ antigenic sin as the fixation cannot be reversed and prejudices the sub-optimal antibody response ‘life-long’) (immune priming and imprinting based on the initial prime or exposure), viral immune escape, and antibody-dependent enhancement of infection (ADEI) and disease (ADED).

This what these studies show. Viral immune escape and OAS operating at full speed. The recall is always to the initial prime.

 

I will provide the references and also the prior substacks and leave this with you yet the situation is straightforward:

Alexander COVID News-Dr. Paul Elias Alexander's Newsletter
Sub-variants BQ.1.1 and BQ.1 account for near 70% of the variants and BA.5 has declined to 11%. XBB is at 4.7% (CDC data); how then, would the bi-valent booster work? Rochelle, here's your answer!
See the Variant Proportions as of today as reported by CDC. We see that BQ.1.1 and BQ.1 account for near 70% of the variants and BA.5 has declined to 11%. XBB is at 4.7%. SOURCE: https://covid.cdc.gov/covid-data-tracker/#variant-proportionsAlexander COVID News-Dr. Paul Elias Alexander's Newsletter is a reader-supported publication. To receive new posts …
Read more

Study 1 for consideration within this prior substack:

Alexander COVID News-Dr. Paul Elias Alexander's Newsletter
We told them this, Vanden Bossche, Yeadon, Alexander, McCullough, Oskoui, Trozzi, Tenenbaum, Risch et al., we did! "Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants"
It is clear that there is original antigenic sin at play (immune fixation or imprinting to the first prime or exposure), viral immune escape, and thus there will be antibody-dependent enhancement of infection and disease. Warning, the concern is not only about a highly infectious sub-variant emerging (driven by the sub-optimal mounting immune pressure) …
Read more

Study 2 for consideration within this prior substack:

Alexander COVID News-Dr. Paul Elias Alexander's Newsletter
COVID Bivalent booster vaccine effectiveness (VE) 'FAILS' again & Shrestha et al. shows us this: "Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine"; VE of 30% (95% CI 20-39%)
Mass vaccination into a pandemic across all age groups and ‘rapid’ mass vaccination at that, while there is massive infectious pressure (circulating virus trying to infect the population) and using a non-neutralizing vaccine whereby the virus has become largely resistant to the vaccine induced antibodies (now non-sterilizing, non-neutralizing so does no…
Read more

Study 3 for consideration within this prior substack:

Alexander COVID News-Dr. Paul Elias Alexander's Newsletter
see study by Kurhade et al. challenging utility of mRNA bivalent booster: "Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster"
I have adjusted the Annual Membership fee: I have reduced the yearly membership fee to $39.99 per year (for those who chose to subscribe with some support yet it can be free as it has always been with no restrictions to comment etc.), which is $3.30 per month and about $0.83 per week and thus $0.11 per day; I am very very grateful for your loyalty and d…
Read more